Agenus Inc To Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress Transcript
Good morning and good afternoon, and welcome to Agenus ESMO GI webcast. We're coming to you live from Barcelona, Spain where we're excited to share with you the remarkable botensilimab/balstilimab combination data we released earlier today in which Dr. Anthony El-Khoueiry presented at ESMO GI's opening session. I am Ethan Lovell, Agenus' Chief Communications Officer, and I'm glad you've been able to join us today.
Before we begin the formal presentation, however, I do need to provide our forward-looking statements disclosure. I'd like to remind you today that this webcast will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and time lines, including time lines for data release and partnership opportunities. These statements are subject to risks and uncertainties, and we refer you to our SEC filings for more details on these risks.
With that housekeeping out of the way, I'd like to invite Dr. Steven OâDay, Agenus' Chief Medical Officer, to the podium to provide some opening commentary Dr. O'Day?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
